Perampanel: a significant liver enzyme inducer in some patients?

Détails

ID Serval
serval:BIB_73F938A4F28D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Perampanel: a significant liver enzyme inducer in some patients?
Périodique
European Neurology
Auteur(s)
Novy J., Rothuizen L.E., Buclin T., Rossetti A.O.
ISSN
1421-9913 (Electronic)
ISSN-L
0014-3022
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
72
Numéro
3-4
Pages
213-216
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Perampanel is one of the latest released antiepileptic drugs (AEDs). Early studies suggest no significant liver enzyme induction from this compound. We report on two patients with medically resistant epilepsy, who had perampanel added to their usual regimen. Both experienced a worsening of their epilepsy and presented in convulsive status epilepticus; concurrent antiepileptic drug levels (phenytoin, phenobarbital, rufinamide) were significantly decreased (<50%) in comparison with levels prior to perampanel introduction. Intravenous load and significant increase of maintenance dosages were needed to restore therapeutic drug levels. In one patient, further increase of perampanel resulted in a new drop of phenytoin level. This suggests that perampanel could, in some subjects, induce liver enzymes and interact with concomitant AEDs; monitoring levels of concomitant compounds could be useful.
Pubmed
Web of science
Création de la notice
30/09/2014 15:21
Dernière modification de la notice
03/03/2018 18:20
Données d'usage